MESO250117P1000
- 0.05
- 0.000.00%
Mesoblast Newsroom
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Trading Halt: Halted at 4:00:59 A.m. ET - Trading Halt: Halt News Pending
Mesoblast Says JPMorgan Chase Reduces Shareholding
Mesoblast Requests Trading Halt
Mesoblast Prepares to Launch FDA-approved Therapy for Pediatric Steroid-Refractory AGVHD | ASX:MSB
Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast Limited Announces Proposed Securities Issue
State Street Corporation Ceases Substantial Holding in Mesoblast
Trending Stocks Today | Treasure Global Shoots up 74.03% Post-Market
January 2nd - US stocks trending post-market.Gainers: $Treasure Global(TGL.US)$ soars 74.03% to $0.33 with a turnover of $5.43 million. $Check-Cap(CHEK.US)$ surges 64.51% to $1.9 with a turnover of $1
Mesoblast Stock Rockets to New 52-Week High
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Mesoblast Shareholder Offers 2M Ordinary Shares Represented By 200K ADSs On Nasdaq Under Symbol "MESO" And Australian Exchange As "MSB"; Company To Receive $9.06 Per ADS Upon Warrant Exercise, No Proceeds From ADS Sales
Mesoblast Sees Major Change in Substantial Holding
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
ASX: Riding the Scariest Rollercoaster on the Sharemarket
This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Jefferies Downgrades Mesoblast to Hold From Buy; Price Target Is AU$2.30
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $30
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $30